ClinicalTrials.gg
RecruitingNCT06132698Updated May 12, 2026

Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

A Phase 2 interventional study of Tislelizumab or pembrolizumab, pemetrexed in NSCLC Associated With Leptomeningeal Metastases, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by West China Hospital · Phase 2, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 487 studies in Neoplasm Metastasis with a site in China — 224 open to participants now, 264 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
372nd of 403
17 · median 90
Started
2023
with 40 others
Phase 2
112 of 487
58 open now
Primary completion
2026-05
later than 81 of 263 live
Registered
303rd of 487
by date

Among the 487 studies in Neoplasm Metastasis with a site in China, this one is the 372nd largest by planned enrollment of the 403 interventional ones that give a count, is one of 41 that started in 2023, is one of 112 in phase 2, reaches primary completion later than 81 of the 263 other live ones, and was the 303rd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

224 of the 487 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

219 more — sign in →

All 224 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 487 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-arm, open clinical study, which was designed to evaluate the efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal injection in the treatment of patients with NSCLC associated with leptomeningeal metastases.

03

Conditions studied

  • NSCLC Associated With Leptomeningeal Metastases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-75 years old, male or female;
  2. Patients with diagnosed non-small cell lung cancer with cerebrospinal fluid and/or MRI diagnosis of ;
  3. (ECOG) performance status of 0 to 4;
  4. Expected survival time of at least 4 weeks;
  5. Oncologist clarification of the potential necessity of receiving systemic therapy for tumors outside the CNS;
  6. Previous radiation therapy, including whole brain radiation, stereotactic radiosurgery, or stereotactic body radiation therapy (SBRT), which must be completed at least 7 days prior to the start of treatment;
  7. Patients who have received approved targeted therapies (EGFR inhibitors, ALK inhibitors, or other targeted therapeutic agents), and other systemic therapies will be allowed to remain on concurrent therapy; concurrent intrathecal therapy with other agents will not be allowed.
  8. Laboratory test indicators meet the following criteria:

    1. Bone marrow function: (Hb) ≥80g/L; white blood cell count (WBC) ≥lower limit of normal; (ANC) ≥1.5×10\^9 /L; count ≥70×109 /L;
    2. Renal function: Cr ≤ (upper limit of normal) × 1.5, endogenous (Ccr) ≥ 55 ml/min;
    3. Liver function: total ≤ ULN × 1.5; and AST ≤ ULN × 2.5; (if there is liver metastasis, total bilirubin is not higher than 3 times the upper limit of normal, and transaminases are not higher than 5 times the upper limit of normal);
    4. Coagulation function: of prothrombin time ≤ ULN × 1.5, and partial thromboplastin time within the normal value;
  9. Females of agree to use during the study period and for 6 months after the completion of the study; patients who have had a negative serum or urine pregnancy test within seven days prior to enrollment in the study and who are not breastfeeding; and males agreeing to use contraception during the study period and for 6 months after the completion of the study;
  10. Those who have not participated in another drug clinical trial within 4 weeks prior to enrollment;
  11. Subjects who can understand the study situation and voluntarily sign the form;
  12. Patients are expected to be compliant and able to follow up on efficacy and adverse events according to protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of other malignant tumors (except carcinoma in situ, basal cell carcinoma, etc.) within the previous 5 years;
  2. History of allergy to pemetrexed and ICIs therapy;
  3. Any previous intrathecal injection therapy;
  4. Rule out differential diagnosis of LM:a. Aseptic meningitis b. Viral meningitis c. Bacterial meningitis;
  5. Participation in other clinical trials or observation periods;
  6. Clinical conditions that would interfere with the evaluation or interpretation of safety or findings, or impede the understanding of and compliance with protocol requirements;
  7. Presence of any treatment-related toxicity from prior systemic antitumor therapy other than alopecia that does not meet grade 1 (based on CTCAE 5.0);
  8. Presence of any active disease or history of autoimmune disease; immunodeficiency, active tuberculosis, ( hepatitis B virus titer HBV-DNA \<500 IU/ml after treatment and if liver function is normal will be allowed), or positive test for virus.
  9. Either disease resulting in permanent or requiring permanent immunosuppressive therapy;
  10. Presence of active infection or serious comorbidities;
  11. uncontrolled epilepsy, neurologic failure, or severe neurologic impairment related to treatment;
  12. Presence of hereditary or acquired bleeding and thrombotic tendencies;
  13. History of severe injury or surgery within 1 month prior to enrollment;
  14. Treatment with a live or attenuated vaccine used for the prevention of infectious diseases within 30 days prior to the first administration (injectable seasonal influenza vaccine is permitted);
  15. Inability to complete an enhanced MRI;
  16. Treatment with immunosuppressive drugs or (> 10 mg prednisone or equivalent per day) within 14 days prior to enrollment; patients are allowed to receive steroid therapy to control CNS-related symptoms, but the dose must ≤ 5 mg per day of dexamethasone (or equivalent); in the absence of an active autoimmune disease, inhaled or topical steroids and adrenal gland replacement dosing are acceptable; alternative therapies (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are permitted; patients with experimental medications that require premedication with corticosteroids are not restricted;
  17. Individuals considered by the investigator to be unsuitable for enrollment.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (estimated)

Study arms

  • Experimental
    Enrolled patients were treated with an immune checkpoint inhibitor combined with pemetrexed intrathe

    Drug: Tislelizumab or pembrolizumab, pemetrexed

Interventions

  • DrugTislelizumab or pembrolizumab, pemetrexed

    Drug 1: Tislelizumab/pembrolizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective response rate (LM ORR) for leptomeningeal metastases.

    Defined as the response to treatment as assessed by the investigator based on the modified Response Assessment in Neuro-Oncology Leptomeningeal Metastases (RANO-LM) criteria, containing cases of complete response, partial response, and major response.

    Time frame: 12 months.

Secondary outcomes

  1. Median Progression-Free Survival (CNS-PFS) in the Central Nervous System.

    Progression-free survival will be measured as time to radiologic, cytologic, or LM-related clinical progression.

    Time frame: Time from the start of intrathecal therapy to radiologic, cytologic, or LM-related clinical progression, whichever outcome occurs first, assessed up to 12 months.

  2. Progression-Free Survival (PFS).

    Progression-free survival will be measured as time to either progression or death.

    Time frame: Time from the first day of administration of study drug until the first efficacy assessment of disease progression (PD) or death from any cause, assessed up to 12 months.

  3. Overall survival (OS).

    Overall survival will be measured as time to death from any cause.

    Time frame: Time from the date of randomisation to the date of death from any cause, assessed up to 12 months.

  4. Disease Control Rate (DCR).

    The DCR was defined as the proportion of patients with the best efficacy (complete response or partial response or stable disease).

    Time frame: 12 months.

  5. Adverse events.

    toxicity values caused by intrathecal injection treatment.

    Time frame: 12 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for May 2026, 30 months after the start.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 30 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 15, 2023
StartActual
Nov 30, 2023
Primary completionEst.
May 30, 2026
CompletionEst.
Jun 30, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06132698
Responsible party
Ting Liu (Clinical Investigator, West China Hospital) — Principal investigator
First posted
Nov 15, 2023
Start date
Nov 30, 2023
Primary completion
May 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
May 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion